Remdesivir could work against new COVID strains - Gilead

Monday, 11. January 2021 15:21

Gilead Sciences CEO Daniel O'Day (pictured) stated on Monday that antiviral drug remdesivir, which has been used for treating patients infected with COVID-19, is "fully expected" to be effective against the new coronavirus strains detected in the United Kingdom and South Africa.

In an interview with CNBC, O'Day explained that "remdesivir works at the source in the cell where the virus replicates, and what we know is in these new variants, that part of the cell is not changing at all in fact." The US biopharmaceutical company tested the drug against more than 2,000 different variants and remdesivir showed "it maintains its effectiveness" against each strain, he stressed.

Earlier on Monday, Gilead revised up its outlook for fiscal 2020, expecting stronger revenue amid better-than-expected remdesivir sales.

Related Links: Gilead Sciences Inc.
Breaking the News / GA